ArticleVascular cell2011
Therapeutic promise and challenges of targeting DLL4/NOTCH1.
Article in Vascular cell, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Review
- Targeting angiogenesis: advances in the design and engineered applications of nanobodies.Frontiers in immunology · 2026Review
- Mechanism of Notch Signaling Pathway in Malignant Progression of Glioblastoma and Targeted Therapy.Biomolecules · 2024Review
- POFUT1 promotes gastric cancer progression through Notch/Wnt dual signaling pathways dependent on the parafibromin-NICD1-β-catenin complex.Journal of the Chinese Medical Association : JCMA · 2023Article
- DLL1 orchestrates CD8Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Biology drives the discovery of bispecific antibodies as innovative therapeutics.Antibody therapeutics · 2020Review
- Targeting cancer stem cells in drug discovery: Current state and future perspectives.World journal of stem cells · 2019Review
- Drug resistance mechanisms of cancer stem-like cells and their therapeutic potential as drug targets.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Targeting Notch signalling pathway of cancer stem cells.Stem cell investigation · 2018Review
- T cells take directions from supporting cast in graft-versus-host disease.The Journal of clinical investigation · 2017Article
- Fibroblastic niches prime T cell alloimmunity through Delta-like Notch ligands.The Journal of clinical investigation · 2017Article
- DLL4/Notch1 and BMP9 Interdependent Signaling Induces Human Endothelial Cell Quiescence via P27KIP1 and Thrombospondin-1.Arteriosclerosis, thrombosis, and vascular biology · 2015Article
- Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.Journal of pharmacokinetics and pharmacodynamics · 2015Review
- Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update.Nature reviews. Clinical oncology · 2015Review
- Notch4 promotes gastric cancer growth through activation of Wnt1/β-catenin signaling.Molecular and cellular biochemistry · 2015Article
- A systems biology view of blood vessel growth and remodelling.Journal of cellular and molecular medicine · 2014Review
- Article
- Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.PloS one · 2014Article
- New Approaches to Target T-ALL.Frontiers in oncology · 2014Review
- Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1.Oncotarget · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DLL4-mediated NOTCH1 signaling represents an essential pathway for vascular development and has emerged as an attractive target for angiogenesis-based cancer therapies. However, newly reported toxicity findings raise safety concerns of chronic pathway blockade. Lessons learned from the development of γ-secretase inhibitors (GSIs) might offer insights into how to safely harness this important signaling pathway.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.